SML3962
LTX-315 trifluoroacetate
≥95% (HPLC)
Synonym(s):
KKWWKKW(Dip)K-NH2 trifluoroacetate, LTX 315 trifluoroacetate, LTX-315 trifluoroacetate, Lys-Lys-Trp-Trp-Lys-Lys-Trp-Dip-Lys-NH2 (Dip = 3,3-diphenylalanine) trifluoroacetate, Ruxotemitide trifluoroacetate
Select a Size
About This Item
Quality Segment
assay
≥95% (HPLC)
form
(Powder or Lyophilized powder or film)
storage condition
desiccated
color
white to off-white
storage temp.
-10 to -25°C
SMILES string
[nH]1c2c(c(c1)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CCCCN)Cc7c8c([nH]c7)cccc8)Cc5c6c([nH]c5)cccc6)CCCCN)CCCCN)C(=O)N[C@@H](C(c4ccccc4)c3ccccc3)C(=O)N[C@@H](CCCCN)C(=O)N)cccc2
InChI key
GGAKLYWEFZCVIT-TVEKFXMRSA-N
Biochem/physiol Actions
LTX-315 (Ruxotemitide) is a 9-mer cationic oncolytic peptide that preferentially permeabilizes mitochondrial membranes, thereby causing partially BAX/BAK1-regulated, caspase-independent necrosis. LTX-315 exhibits cancer-selective cytotoxicity (IC50 = 1.2-7.2 μM among 47 cancer lines; normal MRC-5/HUVEC-C/RBC IC50 = 9.2/16.3/695 μM) with low inhibitory potency toward CYP450 enzymes (IC50 from 7.9 to >100 μM). Intratumoral administration results in B16 melanoma tumor necrosis and the infiltration of immune cells into the tumor parenchyma followed by complete tumor regression in mice in vivo (1 mg/50 μL i.t.). Animals cured by LTX-315 treatment are protected against B16 tumor cells re-challenge.
Disclaimer
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.